Clene to Present at Upcoming May Conferences

Rhea-AI Summary

Clene (Nasdaq: CLNN) will participate in two investor events in early May 2026: a virtual Emerging Growth Conference presentation on May 6, 2026 at 3:25 p.m. ET and one-on-one meetings at the D. Boral Capital Global Conference on May 7, 2026 at The Plaza Hotel, New York.

Presentation access is available via a webcast link and investor meetings are scheduled as 1x1 sessions.

Argus May 5 session

-18.67% close to close Open Argus

Details

News Market Reaction – CLNN

On May 5, the day this news came out, CLNN closed 18.67% below the previous close.

Data tracked by StockTitan Argus for the May 5 session.

Key Figures

Emerging Growth date: May 6, 2026 Presentation time: 3:25 p.m. ET D. Boral Capital date: May 7, 2026

Emerging Growth date

May 6, 2026

Investor conference presentation date

Presentation time

3:25 p.m. ET

Emerging Growth Conference virtual presentation

D. Boral Capital date

May 7, 2026

In-person investor meetings at The Plaza Hotel

Historical Context

5 past events · Latest: May 04

5 events

1. May 04

   Regulatory feedback

   24h Move

   +31.8%

   FDA minutes supporting potential accelerated approval NDA pathway for CNM-Au8 in ALS.

2. Mar 12

   Earnings and financing

   24h Move

   +6.1%

   Full-year 2025 results, narrowed net loss, and oversubscribed registered direct offering.

3. Feb 24

   Pipeline catalysts update

   24h Move

   +9.8%

   Outlined 2026 CNM-Au8 catalysts, including accelerated NDA plans and Phase 3 RESTORE-ALS trial.

4. Feb 19

   Investor conference

   24h Move

   +4.7%

   Announcement of a virtual corporate update at the Emerging Growth Conference.

5. Jan 16

   Investor conference

   24h Move

   -1.2%

   Plan to present a corporate update at the January Emerging Growth Conference.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

amyotrophic lateral sclerosis, multiple sclerosis

2 terms

amyotrophic lateral sclerosis medical

"neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS)"

A progressive disease in which nerve cells that control voluntary muscles gradually fail, leading to loss of movement, speech and eventually breathing — like an electrical wiring system in the body slowly shorting out. It matters to investors because there are few effective treatments, so clinical trial results, regulatory approvals, new therapies or diagnostics can rapidly change patient care, market opportunity and company valuations.

multiple sclerosis medical

"neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS)"

A chronic neurological disease in which the immune system damages the protective coating (like insulation on electrical wires) around nerves, disrupting signals between the brain and body and causing symptoms such as numbness, weakness, vision problems, fatigue and mobility issues. It matters to investors because the unpredictability and long-term nature of the condition drive ongoing demand for treatments, influence the value of companies developing therapies, affect healthcare costs and shape regulatory and reimbursement decisions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SALT LAKE CITY, May 05, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that it will participate in the following investor conferences in May.

Emerging Growth Conference
Date: May 6, 2026
Time of Presentation: 3:25 p.m. ET
Format: Virtual Presentation
Presentation Link: https://goto.webcasts.com/starthere.jsp?ei=1755070&tp_key=280dc3ffe3&sti=clnn

D. Boral Capital Global Conference
Date: May 7, 2026
Location: The Plaza Hotel, New York, New York
Format: 1x1 meetings

About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8^® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8^® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.

Investor Contact: Kevin Gardner, LifeSci Advisors; kgardner@lifesciadvisors.com; (617) 283-2856

Media Contact: Caroline Wagner, Forbes Tate Partners; CWagner@forbes-tate.com; (267) 294-6563 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Clene (CLNN) present at the Emerging Growth Conference in May 2026?

Clene will present virtually on May 6, 2026 at 3:25 p.m. ET. According to the company, the session is a virtual presentation with a provided webcast link for investors to watch the presentation live or via replay.

How can investors access Clene's (CLNN) Emerging Growth Conference presentation on May 6, 2026?

Investors can access the presentation via the company's webcast link. According to the company, the link is provided for the virtual presentation and should allow live viewing and potential replay through the event host's webcast portal.

Will Clene (CLNN) meet investors in person at the D. Boral Capital Global Conference on May 7, 2026?

Clene will hold one-on-one investor meetings at the D. Boral Capital Global Conference on May 7, 2026. According to the company, these are scheduled 1x1 meetings at The Plaza Hotel in New York to engage directly with investors.

What topics will Clene (CLNN) likely cover in its May 2026 investor presentations?

The company will discuss its clinical-stage programs in neurodegenerative diseases such as ALS and MS. According to the company, presentations and meetings will focus on its late clinical-stage development and strategic progress for its therapeutic candidates.

Is the Emerging Growth Conference presentation by Clene (CLNN) available for replay after May 6, 2026?

A replay is typically available through the webcast portal after the live presentation. According to the company, investors can use the provided webcast link to access on-demand replay if the event host posts it post-presentation.

Where and when will Clene (CLNN) participate in investor events during the first week of May 2026?

Clene will participate virtually at the Emerging Growth Conference on May 6, 2026 and hold in-person 1x1 meetings at the D. Boral Capital Global Conference on May 7, 2026. According to the company, the in-person meetings occur at The Plaza Hotel in New York.